Tag archive for ‘Antares Pharma Inc.’
Approval of Anturol Is Significant Positive (AIS, $2.68)
Anturol Approval is A Major Positive Recently, I wrote a note about Anturol discussing its therapeutic profile and the commercialization agreement with Watson. I also wrote an earlier report in which I recommended purchase of Antares. I thought that Anturol had a very high probability for approval, but the FDA has been so risk adverse […]
Anturol’s December 8th PDUFA Date Is Looming (AIS, $2.77)
Introduction I recently began coverage of Antares with a buy. The basis of my recommendation was the exceptional pipeline of drugs that the company is working on. In my initial report, I could not go into great detail on each of these products so that I plan a series of reports that focus on just […]
Antares Initiated As A Buy (AIS, $2.59)
Investment Opinion I am recommending purchase of Antares (AIS) at the current level of $2.59. My 2015 price target is $6.70. Antares has a broad array of products based on its self-injection and gel formulation drug delivery technologies. Its partners are currently marketing four Antares products and there are eight more in development. I estimate […]